We are live on
!
Find out more
TCM
Tamarack Capital Management Portfolio holdings
AUM
$840M
1-Year Est. Return
19.47%
This Fund
S&P 500
This Quarter
Est. Return
+5.78%
1 Year Est. Return
+19.47%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$759M
AUM Growth
+$99.7M
(+15%)
Cap. Flow
+$68.3M
Cap. Flow
% of AUM
9%
Top 10 Holdings %
Top 10 Hldgs %
62.14%
Holding
49
New
10
Increased
19
Reduced
9
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$13.1M |
| 2 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$12.2M |
| 3 |
Becton Dickinson
BDX
|
+$9.18M |
| 4 |
Bio-Techne
TECH
|
+$7.13M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$6.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Quest Diagnostics
DGX
|
+$12.9M |
| 2 |
Myriad Genetics
MYGN
|
+$10.2M |
| 3 |
HNGR
Hanger Inc.
HNGR
|
+$8.31M |
| 4 |
NTUS
Natus Medical Inc
NTUS
|
+$8.04M |
| 5 |
DexCom
DXCM
|
+$6.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 58.29% |
| 2 | Technology | 0.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$778B
| $82.6M | 10.88% |
+400,000
| New | +$82.5M |
|
|
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
| $82.6M | 10.88% |
400,000
-200,000
| -33% | -$41.3M |
|
|
ELGX
3
DELISTED
Endologix Inc
ELGX
| $68.3M | 9% |
400,000
+4,000
| +1% | +$606K |
|
4
PUT
iShares Russell 2000 ETF
IWM
$80.9B
| $49.7M | 6.55% |
+400,000
| New | +$48.2M |
|
|
SPNC
5
DELISTED
Spectranetics Corp
SPNC
| $37.5M | 4.94% |
1,077,596
+52,596
| +5% | +$1.79M |
|
6
Integer Holdings
ITGR
$3.35B
| $33.2M | 4.37% |
629,602
+60,259
| +11% | +$2.86M |
|
|
7
Becton Dickinson
BDX
$43.1B
| $32.9M | 4.33% |
234,725
+65,600
| +39% | +$9.18M |
|
|
8
Quest Diagnostics
DGX
$25.1B
| $30.7M | 4.05% |
400,000
-180,000
| -31% | -$12.9M |
|
9
Medtronic
MDT
$107B
| $29.2M | 3.85% |
375,000
+50,000
| +15% | +$3.79M |
|
10
Teva Pharmaceuticals
TEVA
$35.9B
| $24.9M | 3.28% |
400,000
+15,000
| +4% | +$872K |
|
|
NXTM
11
DELISTED
NxStage Medical Inc.
NXTM
| $22.5M | 2.96% |
1,300,000
+200,000
| +18% | +$3.53M |
|
|
MDRX
12
DELISTED
Veradigm Inc. Common Stock
MDRX
| $17.9M | 2.36% |
1,500,000
+250,000
| +20% | +$3.05M |
|
13
Inogen
INGN
$167M
| $17.6M | 2.32% |
550,000
-124,000
| -18% | -$4M |
|
14
Perrigo
PRGO
$1.4B
| $16.9M | 2.22% |
102,000
+32,000
| +46% | +$5.1M |
|
15
AtriCure
ATRC
$1.77B
| $16.4M | 2.16% |
800,000
+115,000
| +17% | +$2.23M |
|
|
PDCO
16
DELISTED
Patterson Companies, Inc.
PDCO
| $15.5M | 2.04% |
317,945
+17,945
| +6% | +$894K |
|
|
CTRX
17
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| $14.9M | 1.96% |
250,000
+50,000
| +25% | +$2.54M |
|
18
Alkermes
ALKS
$8.82B
| $14.6M | 1.93% |
240,000
-60,000
| -20% | -$4.1M |
|
19
Bio-Rad Laboratories Class A
BIO
$8.42B
| $14.6M | 1.92% |
108,000
+3,000
| +3% | +$372K |
|
|
20
DexCom
DXCM
$27.6B
| $14M | 1.85% |
900,000
-460,000
| -34% | -$6.95M |
|
|
21
Pfizer
PFE
$140B
| $13.6M | 1.79% |
+412,323
| New | +$13.1M |
|
|
KERX
22
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $12.1M | 1.59% |
+950,000
| New | +$12.2M |
|
|
23
Bio-Techne
TECH
$11.2B
| $11.5M | 1.52% |
460,000
+300,000
| +188% | +$7.13M |
|
24
MiMedx Group
MDXG
$626M
| $10.4M | 1.37% |
1,000,000
+350,000
| +54% | +$3.28M |
|
|
LMNX
25
DELISTED
Luminex Corp
LMNX
| $10.1M | 1.33% |
633,092
+133,092
| +27% | +$2.23M |
|
Similar funds
RI
CWA
GHF
F
TRV
BMCMI
GACM
AH
Tamarack Capital Management's Q1 2015 Portfolio in Review
As of Q1 2015, Tamarack Capital Management held 49 positions worth $759M, up 15% from $659M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Tamarack Capital Management deployed $68.3M of net new capital in Q1 2015, opening 10 new positions and adding to 19 existing holdings. Its largest new stake was Pfizer: 412,323 shares worth $13.6M.
By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 59% a quarter earlier, followed by Technology.
On the sell side, the largest reduction was Quest Diagnostics, an estimated $12.9M trimmed.
- Tamarack Capital Management's largest Q1 2015 buy was Pfizer: 412,323 shares worth $13.6M.
- Tamarack Capital Management added most to Becton Dickinson in Q1 2015, an estimated $9.18M increase.
- Tamarack Capital Management's biggest Q1 2015 reduction was Quest Diagnostics, cutting an estimated $12.9M.
- Tamarack Capital Management fully exited Myriad Genetics in Q1 2015, selling an estimated $10.2M.
- Tamarack Capital Management's ten largest holdings make up 62% of its $759M portfolio in Q1 2015.
- Tamarack Capital Management opened 10 new positions and closed 10 in Q1 2015.
- Tamarack Capital Management's portfolio value rose 15% quarter-over-quarter to $759M.
Based on Tamarack Capital Management's 13F filing for Q1 2015, filed 11 May 2015.